<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39386143</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-1078</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in psychology</Title><ISOAbbreviation>Front Psychol</ISOAbbreviation></Journal><ArticleTitle>Fear of progression after cancer recurrence: a mixed methods study.</ArticleTitle><Pagination><StartPage>1479540</StartPage><MedlinePgn>1479540</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1479540</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyg.2024.1479540</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The recurrence of cancer will significantly impact an individual's quality of life (QoL) as they adjust to living with a condition that is often incurable. Patients remain at risk of further progression following recurrence, but fear of cancer progression (FOP) at this time is not commonly examined. Importantly, these fears are known to reach levels in which there are consequences for QoL.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study sought to explore levels of FOP, health-related QoL, anxiety, and depression in patients after a recurrence of their cancer in a longitudinal manner. With the study taking place throughout the COVID-19 pandemic, an assessment of fears related to cancer and the pandemic was included. A sequential mixed method approach was employed for complementarity and expansion purposes. A questionnaire was administered to 44 participants on three different occasions one month apart. A sub-sample of 10 participants then took part in semi-structured interviews.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">FOP was present at moderate levels in patients with a cancer recurrence, with over a third of the sample reaching levels considered dysfunctional. Levels of fear were stable over three months and were not predicted by select demographic or clinical factors. On average, depression was low, but anxiety reached mild levels. Challenges to health-related QoL were evident. Low levels of concern about COVID-19 in relation to cancer were reported. Integrated findings provided more nuanced answers to the research questions, including more specific worries about cancer progression.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="UNASSIGNED">Findings support the development of psychosocial interventions to manage FOP, and future recommendations are provided. Identifying the presence of fears not commonly screened for after cancer recurrence adds to the existing knowledge in this area. Through acknowledging and attending to the psychosocial impact of FOP, healthcare professionals can provide tailored support to enhance the well-being of those with a recurrence of their cancer.</AbstractText><CopyrightInformation>Copyright © 2024 Stewart, Humphris, Donaldson and Cruickshank.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Ross James</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences and Sport, University of Stirling, Stirling, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphris</LastName><ForeName>Gerald Michael</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>School of Medicine, University of St. Andrews, St. Andrews, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donaldson</LastName><ForeName>Jayne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences and Sport, University of Stirling, Stirling, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruickshank</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Royal Marsden NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Psychol</MedlineTA><NlmUniqueID>101550902</NlmUniqueID><ISSNLinking>1664-1078</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer recurrence</Keyword><Keyword MajorTopicYN="N">fear of progression</Keyword><Keyword MajorTopicYN="N">fear of recurrence</Keyword><Keyword MajorTopicYN="N">oncology</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39386143</ArticleId><ArticleId IdType="pmc">PMC11461258</ArticleId><ArticleId IdType="doi">10.3389/fpsyg.2024.1479540</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aggarwal A., Spencer K., Sullivan R. (2023). COVID-19 and cancer in the UK: Which will prove to be the lesser of two evils? BMJ Special. J. 2:e000012. doi: 10.1136/bmjonc-2022-000012</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjonc-2022-000012</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderwick H., Dixon J. (2019). The NHS long term plan. BMJ 364:l84. doi: 10.1136/bmj.l84</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l84</ArticleId><ArticleId IdType="pmc">PMC6350418</ArticleId><ArticleId IdType="pubmed">30617185</ArticleId></ArticleIdList></Reference><Reference><Citation>Alessy S. A., Alhajji M., Rawlinson J., Baker M., Davies E. A. (2022). Factors influencing cancer patients’ experiences of care in the USA, United Kingdom, and Canada: a systematic review. Eclinicalmedicine 47:101405. doi: 10.1016/j.eclinm.2022.101405</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101405</ArticleId><ArticleId IdType="pmc">PMC9046116</ArticleId><ArticleId IdType="pubmed">35497061</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S. N., Elliott R., Silva E. R., Sales C. M. (2019). Fear of cancer recurrence: a qualitative systematic review and meta-synthesis of patients' experiences. Clin. Psychol. Rev. 68, 13–24. doi: 10.1016/j.cpr.2018.12.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpr.2018.12.001</ArticleId><ArticleId IdType="pubmed">30617013</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S. N., Elliott R., Silva E. R., Sales C. M. D. (2022). Emotion-focused therapy for fear of cancer recurrence: a hospital-based exploratory outcome study. Psychotherapy 59, 261–270. doi: 10.1037/pst0000389, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/pst0000389</ArticleId><ArticleId IdType="pubmed">34990161</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K., Smith A. B., Diaz A., Shaw J., Butow P., Sharpe L., et al. . (2021). A systematic review of fear of cancer recurrence among indigenous and minority peoples. Front. Psychol. 12:621850. doi: 10.3389/fpsyg.2021.621850</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.621850</ArticleId><ArticleId IdType="pmc">PMC8126623</ArticleId><ArticleId IdType="pubmed">34012412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban Y., Li M., Yu M., Wu H. (2021). The effect of fear of progression on quality of life among breast cancer patients: the mediating role of social support. Health Qual. Life Outcomes 19, 1–9. doi: 10.1186/s12955-021-01816-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-021-01816-7</ArticleId><ArticleId IdType="pmc">PMC8276515</ArticleId><ArticleId IdType="pubmed">34253195</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone B., De Luca L., Napolitano L., Reccia P., Crocetto F., Creta M., et al. . (2022). Lower urinary tract symptoms and mental health during COVID-19 pandemic. Archivio Italiano di Urologia e Andrologia 94, 46–50. doi: 10.4081/aiua.2022.1.46, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/aiua.2022.1.46</ArticleId><ArticleId IdType="pubmed">35352524</ArticleId></ArticleIdList></Reference><Reference><Citation>Beller J., Geyer S., Epping J. (2022). Health and study dropout: health aspects differentially predict attrition. BMC Med. Res. Methodol. 22:31. doi: 10.1186/s12874-022-01508-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-022-01508-w</ArticleId><ArticleId IdType="pmc">PMC8802529</ArticleId><ArticleId IdType="pubmed">35094681</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun V., Clarke V. (2006). Using thematic analysis in psychology. Qual. Res. Psychol. 3, 77–101. doi: 10.1191/1478088706qp063oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1478088706qp063oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Butow P., Müller F., Napier C. E., Bartley N., Ballinger M. L., Biesecker B., et al. . (2021). Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. Psycho-Oncology 30, 1920–1929. doi: 10.1002/pon.5764, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.5764</ArticleId><ArticleId IdType="pubmed">34240516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Chung J. O. K., Lam K. K. W., Molassiotis A. (2023). End-of-life communication strategies for healthcare professionals: a scoping review. Palliat. Med. 37, 61–74. doi: 10.1177/02692163221133670, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02692163221133670</ArticleId><ArticleId IdType="pubmed">36349371</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutts-Bain D., Sharpe L., Pradhan P., Russell H., Heathcote L. C., Costa D. (2022). Are fear of cancer recurrence and fear of progression equivalent constructs? Psycho Oncol. 31, 1381–1389. doi: 10.1002/pon.5944</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.5944</ArticleId><ArticleId IdType="pmc">PMC9545421</ArticleId><ArticleId IdType="pubmed">35470502</ArticleId></ArticleIdList></Reference><Reference><Citation>Creswell J. W., Clark V. L. P. (2017). Designing and conducting mixed methods research. Washington, DC: Sage publications.</Citation></Reference><Reference><Citation>Crist J. V., Grunfeld E. A. (2013). Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psycho-Oncology 22, 978–986. doi: 10.1002/pon.3114, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.3114</ArticleId><ArticleId IdType="pubmed">22674873</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocetto F., Buonerba L., Scafuri L., Caputo V., Barone B., Sciarra A., et al. . (2022). COVID-19 and prostate cancer: A complex scenario with multiple facets. Oxfordshire: Taylor &amp; Francis.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621215</ArticleId><ArticleId IdType="pubmed">34898669</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawadi S., Shrestha S., Giri R. A. (2021). Mixed-methods research: a discussion on its types, challenges, and criticisms. J. Pract. Stud. Educ. 2, 25–36. doi: 10.46809/jpse.v2i2.20</Citation><ArticleIdList><ArticleId IdType="doi">10.46809/jpse.v2i2.20</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuning-Smit E., Custers J. A., Miroševič Š., Takes R. P., Jansen F., Langendijk J. A., et al. . (2022). Prospective longitudinal study on fear of cancer recurrence in patients newly diagnosed with head and neck cancer: course, trajectories, and associated factors. Head Neck 44, 914–925. doi: 10.1002/hed.26985</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.26985</ArticleId><ArticleId IdType="pmc">PMC9305148</ArticleId><ArticleId IdType="pubmed">35084079</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillekås H., Rogers M. S., Straume O. (2019). Are 90% of deaths from cancer caused by metastases? Cancer Med. 8, 5574–5576. doi: 10.1002/cam4.2474, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.2474</ArticleId><ArticleId IdType="pmc">PMC6745820</ArticleId><ArticleId IdType="pubmed">31397113</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel A., Herschbach P. (2017). Fear of progression in Cancer patients and survivors. Psycho-Oncology, 13–33. doi: 10.1007/978-3-319-64310-6_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-64310-6_2</ArticleId><ArticleId IdType="pubmed">28924677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro M., Del Giudice F., Carrieri G., Busetto G. M., Cormio L., Hurle R., et al. . (2021). The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a retrospective multi-institutional cohort analysis. Cancers 13:5276. doi: 10.3390/cancers13215276</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13215276</ArticleId><ArticleId IdType="pmc">PMC8582553</ArticleId><ArticleId IdType="pubmed">34771440</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetters M. D., Curry L. A., Creswell J. W. (2013). Achieving integration in mixed methods designs—principles and practices. Health Serv. Res. 48, 2134–2156. doi: 10.1111/1475-6773.12117, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1475-6773.12117</ArticleId><ArticleId IdType="pmc">PMC4097839</ArticleId><ArticleId IdType="pubmed">24279835</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugmann D., Richter P., Karger A., Ernstmann N., Hönig K., Bergelt C., et al. . (2023). Caring for dependent children impacts practical and emotional problems and need for support, but not perceived distress among cancer patients. Psycho-Oncology 32, 1231–1239. doi: 10.1002/pon.6173, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.6173</ArticleId><ArticleId IdType="pubmed">37277899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganti A. K., Hirsch F. R., Wynes M. W., Ravelo A., Ramalingam S. S., Ionescu-Ittu R., et al. . (2017). Access to cancer specialist care and treatment in patients with advanced stage lung cancer. Clin. Lung Cancer 18:e2. doi: 10.1016/j.cllc.2017.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cllc.2017.04.010</ArticleId><ArticleId IdType="pubmed">28522158</ArticleId></ArticleIdList></Reference><Reference><Citation>Götze H., Taubenheim S., Dietz A., Lordick F., Mehnert-Theuerkauf A. (2019). Fear of cancer recurrence across the survivorship trajectory: results from a survey of adult long-term cancer survivors. Psycho-Oncology 28, 2033–2041. doi: 10.1002/pon.5188, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.5188</ArticleId><ArticleId IdType="pubmed">31364222</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths P., Simon M., Richardson A., Corner J. (2013). Is a larger specialist nurse workforce in cancer care associated with better patient experience? Cross-sectional study. J. Health Serv. Res. Policy 18, 39–46. doi: 10.1177/1355819612473451, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1355819612473451</ArticleId><ArticleId IdType="pubmed">27552778</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M., Gudex C., Lloyd A., Janssen M., Kind P., Parkin D., et al. . (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20, 1727–1736. doi: 10.1007/s11136-011-9903-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinz A., Mehnert A., Ernst J., Herschbach P., Schulte T. (2015). Fear of progression in patients 6 months after cancer rehabilitation—a validation study of the fear of progression questionnaire FoP-Q-12. Support. Care Cancer 23, 1579–1587. doi: 10.1007/s00520-014-2516-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-014-2516-5</ArticleId><ArticleId IdType="pubmed">25412727</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphris G., Watson E., Sharpe M., Ozakinci G. (2018). Unidimensional scales for fears of cancer recurrence and their psychometric properties: the FCR4 and FCR7. Health Qual. Life Outcomes 16:30. doi: 10.1186/s12955-018-0850-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-018-0850-x</ArticleId><ArticleId IdType="pmc">PMC5822647</ArticleId><ArticleId IdType="pubmed">29471823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakens D. (2022). Sample size justification. Collabra 8:33267. doi: 10.1525/collabra.33267</Citation><ArticleIdList><ArticleId IdType="doi">10.1525/collabra.33267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebel S., Ozakinci G., Humphris G., Mutsaers B., Thewes B., Prins J., et al. . (2016). From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support. Care Cancer 24, 3265–3268. doi: 10.1007/s00520-016-3272-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-016-3272-5</ArticleId><ArticleId IdType="pubmed">27169703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee-Jones C., Humphris G., Dixon R., Bebbington Hatcher M. (1997). Fear of Cancer recurrence – a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psycho-Oncology 6, 95–105, PMID:</Citation><ArticleIdList><ArticleId IdType="pubmed">9205967</ArticleId></ArticleIdList></Reference><Reference><Citation>Leventhal H., Brissette I., Leventhal E. A. (2012). The common-sense model of self-regulation of health and illness. The self-regulation of health and illness behaviour. London: Routledge, 43–66.</Citation></Reference><Reference><Citation>Lisy K., Kent J., Piper A., Jefford M. (2021). Facilitators and barriers to shared primary and specialist cancer care: a systematic review. Support. Care Cancer 29, 85–96. doi: 10.1007/s00520-020-05624-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-020-05624-5</ArticleId><ArticleId IdType="pubmed">32803729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X., Wu C., Bai D., You Q., Cai M., Wang W., et al. . (2023). Relationship between social support and fear of cancer recurrence among Chinese cancer patients: a systematic review and meta-analysis. Front. Psych. 14:1136013. doi: 10.3389/fpsyt.2023.1136013</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2023.1136013</ArticleId><ArticleId IdType="pmc">PMC10031045</ArticleId><ArticleId IdType="pubmed">36970291</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrudden M. T., Marchand G., Schutz P. A. (2021). Joint displays for mixed methods research in psychology. Methods Psychol. 5:100067. doi: 10.1016/j.metip.2021.100067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metip.2021.100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehnert A., Herschbach P., Berg P., Henrich G., Koch U. (2006). Fear of progression in breast cancer patients--validation of the short form of the fear of progression questionnaire (FoP-Q-SF). Z Psychosom Med Psychothe 52, 274–288. doi: 10.13109/zptm.2006.52.3.274</Citation><ArticleIdList><ArticleId IdType="doi">10.13109/zptm.2006.52.3.274</ArticleId><ArticleId IdType="pubmed">17156600</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu L., Liang Y., Niu M. (2019). Factors influencing fear of cancer recurrence in patients with breast cancer: evidence from a survey in Yancheng, China. J. Obstet. Gynaecol. Res. 45, 1319–1327. doi: 10.1111/jog.13978, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jog.13978</ArticleId><ArticleId IdType="pubmed">31016820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocloo J., Garfield S., Franklin B. D., Dawson S. (2021). Exploring the theory, barriers and enablers for patient and public involvement across health, social care and patient safety: a systematic review of reviews. Health Res. Policy Syst. 19, 1–21. doi: 10.1186/s12961-020-00644-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00644-3</ArticleId><ArticleId IdType="pmc">PMC7816359</ArticleId><ArticleId IdType="pubmed">33472647</ArticleId></ArticleIdList></Reference><Reference><Citation>Riggio A. I., Varley K. E., Welm A. L. (2021). The lingering mysteries of metastatic recurrence in breast cancer. Br. J. Cancer 124, 13–26. doi: 10.1038/s41416-020-01161-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-020-01161-4</ArticleId><ArticleId IdType="pmc">PMC7782773</ArticleId><ArticleId IdType="pubmed">33239679</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiler A., Jenewein J. (2019). Resilience in cancer patients. Front. Psych. 10:208. doi: 10.3389/fpsyt.2019.00208</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00208</ArticleId><ArticleId IdType="pmc">PMC6460045</ArticleId><ArticleId IdType="pubmed">31024362</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim E. J., Shin Y. W., Oh D. Y., Hahm B. J. (2010). Increased fear of progression in cancer patients with recurrence. Gen. Hosp. Psychiatry 32:169. doi: 10.1016/j.genhosppsych.2009.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2009.11.017</ArticleId><ArticleId IdType="pubmed">20302991</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard S., Thewes B., Humphris G., Dixon M., Hayden C., Mireskandari S., et al. . (2013). Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J. Cancer Survivor. 7, 300–322. doi: 10.1007/s11764-013-0272-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-013-0272-z</ArticleId><ArticleId IdType="pubmed">23475398</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonelli L. E., Siegel S. D., Duffy N. M. (2017). Fear of cancer recurrence: a theoretical review and its relevance for clinical presentation and management. Psycho-Oncology 26, 1444–1454. doi: 10.1002/pon.4168, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4168</ArticleId><ArticleId IdType="pubmed">27246348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R. J., Humphris G. M., Donaldson J., Cruickshank S. (2021). Does Cancer type influence the impact of recurrence? A review of the experience of patients with breast or prostate Cancer recurrence. Front. Psychol. 12:2573. doi: 10.3389/fpsyg.2021.635660</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.635660</ArticleId><ArticleId IdType="pmc">PMC8276075</ArticleId><ArticleId IdType="pubmed">34267696</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D., Fang H., Wang J., Wu J. (2024). Group-based trajectory modeling for fear of cancer recurrence in cancer survivors: a systematic review. J. Cancer Surviv., 1–19. doi: 10.1007/s11764-024-01582-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-024-01582-7</ArticleId><ArticleId IdType="pubmed">38584241</ArticleId></ArticleIdList></Reference><Reference><Citation>Taber K. S. (2018). The use of Cronbach’s alpha when developing and reporting research instruments in science education. Res. Sci. Educ. 48, 1273–1296. doi: 10.1007/s11165-016-9602-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11165-016-9602-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauber N. M., O’Toole M. S., Dinkel A., Galica J., Humphris G., Lebel S., et al. . (2019). Effect of psychological intervention on fear of cancer recurrence: a systematic review and meta-analysis. J. Clin. Oncol. 37:2899. doi: 10.1200/JCO.19.00572</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.00572</ArticleId><ArticleId IdType="pmc">PMC6823887</ArticleId><ArticleId IdType="pubmed">31532725</ArticleId></ArticleIdList></Reference><Reference><Citation>Teglia F., Angelini M., Casolari G., Astolfi L., Boffetta P. (2022). Global association of COVID-19 pandemic measures with cancer treatment: a systematic review and meta-analysis. Cancers 14:5490. doi: 10.3390/cancers14225490</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14225490</ArticleId><ArticleId IdType="pmc">PMC9688091</ArticleId><ArticleId IdType="pubmed">36428583</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernooij F., Heintz A. P. M., Coebergh J.-W., Massuger L. F., Witteveen P. O., van der Graaf Y. (2009). Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol. Oncol. 112, 455–461. doi: 10.1016/j.ygyno.2008.11.011, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2008.11.011</ArticleId><ArticleId IdType="pubmed">19136148</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt J., Beyer F., Sistermanns J., Kuon J., Kahl C., Alt-Epping B., et al. . (2021). Symptom burden and palliative care needs of patients with incurable cancer at diagnosis and during the disease course. Oncologist 26, e1058–e1065. doi: 10.1002/onco.13751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/onco.13751</ArticleId><ArticleId IdType="pmc">PMC8176980</ArticleId><ArticleId IdType="pubmed">33687742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanzer M. B., Czapla J. (2022). “I looked it up and you’ll probably be fine”: cancer survivors’ perceptions of helpful and unhelpful support messages and sources. Commun. Q. 70, 382–406. doi: 10.1080/01463373.2022.2074303</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01463373.2022.2074303</ArticleId></ArticleIdList></Reference><Reference><Citation>White R., Stanley F., Than J., Macnair A., Pethick J., Fallica G., et al. . (2021). Treatable but not curable cancer in England: a retrospective cohort study using cancer registry data and linked data sets. BMJ Open 11:e040808. doi: 10.1136/bmjopen-2020-040808</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-040808</ArticleId><ArticleId IdType="pmc">PMC7798682</ArticleId><ArticleId IdType="pubmed">33419907</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Zheng Y., Sun Z., Humphris G. (2023). Does fear of infection affect people’s dental attendance during COVID-19? A Chinese example to examine the association between COVID anxiety and dental anxiety. Front. Oral Health 4:1236387. doi: 10.3389/froh.2023.1236387</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/froh.2023.1236387</ArticleId><ArticleId IdType="pmc">PMC10591092</ArticleId><ArticleId IdType="pubmed">37876531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond A. S., Snaith R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361–370, PMID:</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>